Cited by 1,454Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model OrganismsFOXO transcription factor regulation

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

Open access
Baar, Marjolein P., Brandt, Renata M.C., Putavet, Diana A., Klein, Julian D.D., Derks, Kasper W.J., Bourgeois, Benjamin R.M., Stryeck, Sarah, Rijksen, Yvonne +13 more·2017·Cell

Abstract

The accumulation of irreparable cellular damage restricts healthspan after acute stress or natural aging. Senescent cells are thought to impair tissue function, and their genetic clearance can delay features of aging. Identifying how senescent cells avoid apoptosis allows for the prospective design of anti-senescence compounds to address whether homeostasis can also be restored. Here, we identify FOXO4 as a pivot in senescent cell viability. We designed a FOXO4 peptide that perturbs the FOXO4 interaction with p53. In senescent cells, this selectively causes p53 nuclear exclusion and cell-intrinsic apoptosis. Under conditions where it was well tolerated in vivo, this FOXO4 peptide neutralized doxorubicin-induced chemotoxicity. Moreover, it restored fitness, fur density, and renal function in both fast aging Xpd TTD/TTD and naturally aged mice. Thus, therapeutic targeting of senescent cells is feasible under conditions where loss of health has already occurred, and in doing so tissue homeostasis can effectively be restored.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2017.02.031

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In senescent cells, FOXO4 binds p53 and keeps it in the nucleus; disrupting this interaction with an inverse peptide causes p53 to leave the nucleus, triggering cytochrome c release from mitochondria and apoptosis.

    “In senescent cells, FOXO4 binds to p53 to localize it to the nucleus. If this interaction is disrupted by the administration of an inverse peptide, p53 is excluded from the nucleus, initiating cytochrome c release from the mitochondria and apoptosis206.”

    From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [206]

    The Results section on FOXO4-DRI reports that the peptide competes with FOXO4 for p53 binding, excludes active p53 from the nucleus, and induces apoptosis in senescent cells (page unavailable). The paper reports mitochondrial cytochrome c release after FOXO4 inhibition by shRNA, not specifically after administration of FOXO4-DRI; that step in the claimed peptide-induced sequence is not established by our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • The peptide proxofim induces senolysis by disrupting the interaction between p53 and FOXO4.

    “Administration of proxofim (a peptide) promotes senolysis by interfering with the binding of p53 to forkhead box protein O4 (FOXO4)206.”

    From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [206]

    The Results section reports that the peptide FOXO4-DRI competes with FOXO4 for p53 binding and selectively induces apoptosis in senescent cells. Our copy does not name the peptide proxofim or establish that proxofim is FOXO4-DRI, so it does not verify that part of the claim. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • In Xpd TTD/TTD mice, treatment with FOXO4-DRI peptide disrupted FOXO4 interaction with p53, documenting a role for senescence in driving aging.

    “the role of senescence in driving aging in the Xpd TTD/TTD was clearly documented by the fact that treatment with a D-retro inverso (DRI-)isoform peptide of FOXO4 was able to disrupt FOXO4 interaction with p53”

    From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Baar et al., 2017

    The Results section on FOXO4–p53 reports that FOXO4-DRI competes with FOXO4 for p53 binding. The Results section on XpdTTD/TTD mice reports reduced senescence and improved features of frailty after treatment. The copy does not show that the interaction was measured in those mice, so the sentence joins a demonstrated peptide mechanism to the mouse findings more directly than the paper does. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • FOXO4 retains p53 in the nucleus, so peptides that interfere with this interaction can cause p53-mediated apoptosis in some senescent cells.

    “forkhead box O4 (FOXO4) retains p53 in the nucleus, so peptides interfering with this interaction can lead to p53-mediated apoptosis in some types of senescent cells87.”

    From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [87]

  • A peptide that blocks the p53-FOXO4 interaction causes apoptosis of senescent cells in vitro and in vivo and improves fitness, hair growth, and renal function in progeroid and aged mice.

    “In addition, a peptide that blocks the interaction of p53 with FOXO4 (a forkhead transcription factor family member that binds p53 to induce cellular senescence) induces apoptosis of Sncs in vitro and in vivo, improving fitness, hair growth, and renal function in progeroid and aged mice (29).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 61 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Baar, M. P., Brandt, R. M. C., Putavet, D. A., Klein, J. D. D., Derks, K. W. J., Bourgeois, B. R. M., Stryeck, S., Rijksen, Y., van Willigenburg, H., Feijtel, D. A., van der Pluijm, I., Essers, J., van Cappellen, W. A., van IJcken, W. F., Houtsmuller, A. B., Pothof, J., de Bruin, R. W. F., Madl, T., Hoeijmakers, J. H. J., Campisi, J., & de Keizer, P. L. J.
Affiliations
  • Erasmus MC (NL)
  • Medical University of Graz (AT)
  • Buck Institute for Research on Aging (US)
Venue
Cell
Publisher
Elsevier BV
Published
2017-03
Volume
169
Issue
1
Pages
132-147.e16
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2599353531
Cited by
1,454
References
61
Citations by year
2026: 109 · 2025: 149 · 2024: 173 · 2023: 145 · 2022: 177 · 2021: 169 · 2020: 184 · 2019: 160 · 2018: 124 · 2017: 62 · 2013: 1
FWCI
107.28
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • PubMed Central (acceptedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • KWF Kankerbestrijding (EMCR 2014-7141)
  • National Institutes of Health (R37-AG009909)
  • Erasmus Universitair Medisch Centrum Rotterdam
  • National Institute on Aging (PPG AG-17242-02)
  • Koninklijke Nederlandse Akademie van Wetenschappen
  • Nierstichting (15OP11)
  • Austrian Science Fund (DK-MCD W1226, FWF P28854)
Topics
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › FOXO transcription factor regulation
Keywords
senescent cells, apoptosis, FOXO4, p53, senolytics, tissue homeostasis, aging, chemotherapy toxicity, doxorubicin, healthspan, renal function
MeSH terms
Aging, Animals, Antibiotics, Antineoplastic, Cell Line, Cell Survival, Inclusion Bodies, Doxorubicin, Female, Fibroblasts, Humans, Kidney, Liver, Male, Tumor Suppressor Protein p53, Cellular Senescence, Apoptosis, Cell Cycle Proteins, Mice, Forkhead Transcription Factors, Trichothiodystrophy Syndromes, Cell-Penetrating Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review